Nomegestrol acetate: Pharmacology, safety profile and therapeutic efficacy

Drugs

Volumn 70, Issue 5, 2010, Pages 541-559

  Lello, Stefano ^a  

^a LABORATORIO DI PATOLOGIA VASCOLARE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CHLORMADINONE; CYPROTERONE; DESOGESTREL; DIENOGEST; DROSPIRENONE; DYDROGESTERONE; ESTRADIOL; ESTROGEN; ETONOGESTREL; GESTAGEN; GESTODENE; LEVONORGESTREL; MEDROXYPROGESTERONE; MEDROXYPROGESTERONE ACETATE; MEGESTEROL; NITRIC OXIDE; NOMEGESTROL; NOMEGESTROL ACETATE; NORETHISTERONE; NORGESTIMATE; NORGESTREL; PROGESTERONE; PROGESTERONE RECEPTOR; PROMEGESTONE; STEROID RECEPTOR; UNCLASSIFIED DRUG;

ASTHENIA; BLEEDING; BLOATING; BLOOD PRESSURE; BODY WEIGHT; BONE REMODELING; BONE TURNOVER; BREAST; BREAST CANCER; BREAST TENDERNESS; CANCER RISK; CARDIOVASCULAR RISK; CELL PROLIFERATION; CLINICAL TRIAL; DRUG ABSORPTION; DRUG CLASSIFICATION; DRUG EFFECT; DRUG EFFICACY; DRUG EXCRETION; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG METABOLISM; DRUG RECEPTOR BINDING; DRUG SAFETY; DRUG STRUCTURE; DRUG TOLERABILITY; DYSMENORRHEA; ENDOMETRIUM; ENDOMETRIUM HYPERPLASIA; ENDOTHELIUM CELL; GLUCOSE METABOLISM; GYNECOLOGIC DISEASE; HORMONAL CONTRACEPTION; HORMONE SUBSTITUTION; HOT FLUSH; HUMAN; HYPOTHALAMUS HYPOPHYSIS SYSTEM; IMPLANT; INSOMNIA; MASTALGIA; MENOPAUSAL SYNDROME; MENOPAUSE; MENORRHAGIA; MENSTRUATION DISORDER; METRORRHAGIA; MULTIPLE CYCLE TREATMENT; NAUSEA; ORAL CONTRACEPTION; OVARY FOLLICLE DEVELOPMENT; OVULATION INHIBITION; PELVIS PAIN SYNDROME; PREMENSTRUAL SYNDROME; REVIEW; SIDE EFFECT; SPOTTING; THROMBOEMBOLISM; UTERUS DISEASE;

ANIMALS; BONE REMODELING; BREAST NEOPLASMS; CARDIOVASCULAR DISEASES; CONTRACEPTIVES, ORAL, HORMONAL; ENDOMETRIAL HYPERPLASIA; FEMALE; HORMONE REPLACEMENT THERAPY; HUMANS; MEGESTROL; NORPREGNADIENES; PROGESTERONE CONGENERS; RISK ASSESSMENT; RISK FACTORS; THROMBOEMBOLISM; TREATMENT OUTCOME;

EID: 77949941545     PISSN: 00126667     EISSN: 11791950     Source Type: Journal    
DOI: 10.2165/11532130-000000000-00000     Document Type: Review

References (66)

1. Kuhl H. Comparative pharmacology of newer progestogens. Drugs 1996 Feb; 51 (2): 188-215
2. Sitruk-Ware R. New progestogens: a review of their effects in perimenopausal and postmenopausal women. Drugs Aging 2004; 21 (13): 865-883
3. Schindler AE, Campagnoli C, Druckmann R, et al. Classification and pharmacology of progestins. Maturitas 2003 Dec 10; 46 Suppl. 1: S7-16
4. Sitruk-Ware R. Pharmacological profile of progestins. Maturitas 2004 Apr 15; 47 (4): 277-283
5. Sitruk-Ware R. New progestagens for contraceptive use. Hum Reprod Update 2006 Mar-Apr; 12 (2): 169-178
6. Pasqualini JR. Progestins and breast cancer. Gynecol Endocrinol 2007 Oct; 23 Suppl. 1: 32-41
7. Kumar N, Koide SS, Tsong Y, et al. Nestorone: a progestin with a unique pharmacological profile. Steroids 2000 Oct-Nov; 65 (10-11): 629-636
8. Paris J, Thevenot R, Bonnet P, et al. The pharmacological profile of TX 066 (17 alpha-acetoxy-6-methyl-19-nor-4,6-pregna-diene-3,20-dione), a new oral progestative. Arz-neimittelforschung 1983; 33 (5): 710-715
9. Duc I, Botella J, Bonnet P, et al. Antiandrogenic properties of nomegestrol acetate. Arzneimittelforschung 1995 Jan; 45 (1): 70-4 10.
10. Bullock LP, Bardin CW. Androgenic, synandrogenic, and antiandrogenic actions of progestins. Ann N Y Acad Sci 1977 Mar 11; 286: 321-330
11. Bazin B, Thevenot R, Bursaux C, et al. Effect of nomegestrol acetate, a new 19-nor-progesterone derivative, on pituitary-ovarian function in women. Br J Obstet Gynaecol 1987 Dec; 94 (12): 1199-1204
12. Couzinet B, Young J, Kujas M, et al. The antigonadotropic activity of a 19-nor-progesterone derivative is exerted both at the hypothalamic and pituitary levels in women. J Clin Endocrinol Metab 1999 Nov; 84 (11): 4191-4196
13. Couzinet B, Young J, Brailly S, et al. The antigonadotropic activity of progestins (19-nortestosterone and 19-norpro-gesterone derivatives) is not mediated through the andro-gen receptor. J Clin Endocrinol Metab 1996 Dec; 81 (12): 4218-23 Data on file, Theramex S.p.A., 2002
14. Theramex S.p.A., 2002 Ezan E, Benech H, Bucourt R, et al. Enzyme immunoassay for nomegestrol acetate in human plasma. J Steroid Bio-chem Mol Biol 1993 Oct; 46 (4): 507-514
15. Dusterberg B, Humpel M, Speck U. Terminal half-lives in plasma and bioavailability of norethisterone, levonorges-trel, cyproterone acetate and gestodene in rats, beagles and rhesus monkeys. Contraception 1981 Dec; 24 (6): 673-683
16. Cohen A. Multicenter study of the clinical use of nomegestrol acetate in outpatients. Contracept Fertil Sex (Paris) 1994; 21: 417-427
17. Cohen A, Engelmann P, Erny R, et al. Lutenyl and menstrual disorders: a hospital study. Rev Fr Gynecol Obstet 1988 Nov; 83 (11): 741-743
18. Persiani P, Radici E, Lombardi PA, et al. Use of nomegestrol acetate in the treatment of menstruation disorders: our experience in 56 cases. Minerva Ginecol 1997 Apr; 49 (4): 181-185
19. Conard J, Basdevant A, Thomas JL, et al. Cardiovascular risk factors and combined estrogen-progestin replacement therapy: a placebo-controlled study with nomegestrol acetate and estradiol. Fertil Steril 1995 Nov; 64 (5): 957-962
20. Fraser DI, Padwick ML, Whitehead MI, et al. The effects of the addition of nomegestrol acetate to post-menopausal oestrogen therapy. Maturitas 1989 Mar; 11 (1): 21-34
21. De Leo V, la Marca A, Morgante G, et al. Comparison of two HRT regimens with bimonthly and monthly progestin administration in postmenopause. Maturitas 1999 Jan 4; 31 (2): 171-177
22. Di Carlo C, Sammartino A, Di Spiezio Sardo A, et al. Bleeding patterns during continuous estradiol with different sequential progestogens therapy. Menopause 2005 Sep-Oct; 12 (5): 520-525
23. Chretien FC, Dubois R. Effect of nomegestrol acetate on spinability, ferning and mesh dimension of midcycle cervical mucus. Contraception 1991 Jan; 43 (1): 55-65
24. Coutinho EM. One year contraception with a single subdermal implant containing nomegestrol acetate (Uniplant). Contraception 1993 Jan; 47 (1): 97-105
25. Devoto L, Kohen P, Barnhart K, et al. Hormonal profile, endometrial histology and ovarian ultrasound assessment during 1 year of nomegestrol acetate implant (Uniplant). Hum Reprod 1997 Apr; 12 (4): 708-713
26. Basdevant A, Pelissier C, Conard J, et al. Effects of nomegestrol acetate (5mg/d) on hormonal, metabolic and hemostatic parameters in premenopausal women. Contraception 1991 Dec; 44 (6): 599-605
27. Daly E, Vessey MP, Hawkins MM, et al. Risk of venous thromboembolism in users of hormone replacement therapy. Lancet 1996 Oct 12; 348 (9033): 977-980
28. Jick H, Derby LE, Myers MW, et al. Risk of hospital admission for idiopathic venous thromboembolism among users of postmenopausal oestrogens. Lancet 1996 Oct 12; 348 (9033): 981-983
29. Perez Gutthann S, Garcia Rodriguez LA, Castellsague J, et al. Hormone replacement therapy and risk of venous thromboembolism: population based case-control study. BMJ 1997 Mar 15; 314 (7083): 796-800
30. Rosendaal FR, Helmerhorst FM, Vandenbroucke JP. Oral contraceptives, hormone replacement therapy and thrombosis. Thromb Haemost 2001 Jul; 86 (1): 112-123
31. Bloemenkamp KW, Rosendaal FR, Helmerhorst FM, et al. Enhancement by factor V Leiden mutation of risk of deep-vein thrombosis associated with oral contraceptives containing a third-generation progestagen. Lancet 1995 Dec 16; 346 (8990): 1593-1596
32. Jick H, Kaye JA, Vasilakis-Scaramozza C, et al. Risk of venous thromboembolism among users of third generation oral contraceptives compared with users of oral contraceptives with levonorgestrel before and after 1995: cohort and case-control analysis. BMJ 2000 Nov 11; 321 (7270): 1190-1195
33. World Health Organization Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. Effect of different progestagens in low oestrogen oral contraceptives on venous thromboembolic disease. Lancet 1995 Dec 16; 346 (8990 1582-1588.
34. Zerr-Fouineau M, Chataigneau M, Blot C, et al. Progestins overcome inhibition of platelet aggregation by endothelial cells by down-regulating endothelial NO synthase via gluco-corticoid receptors. FASEB J 2007 Jan; 21 (1): 265-273
35. Zerr-Fouineau M, Jourdain M, Boesch C, et al. Certain progestins prevent the enhancing effect of 17{beta}-estradiol on NO-mediated inhibition of platelet aggregation by en-dothelial cells. Arterioscler Thromb Vasc Biol 2009; 29 (4): 586-593
36. Scarabin PY, Oger E, Plu-Bureau G. Differential association of oral and transdermal oestrogen-replacement therapy with venous thromboembolism risk. Lancet 2003 Aug 9; 362 (9382): 428-432
37. Canonico M, Oger E, Plu-Bureau G, et al. Hormone therapy and venous thromboembolism among postmenopausal women: impact of the route of estrogen administration and progestogens: the ESTHER study. Circulation 2007 Feb 20; 115 (7): 840-845
38. Canonico M, Oger E, Plu-Bureau G, et al. Response to letter regarding article, "Hormone therapy and venous throm-boembolism among postmenopausal women: impact of the route of estrogen administration and progestogens: the ESTHER study" [letter]. Circulation 2007; 116: e363
39. Post MS, Hendriks DF, Van Der Mooren MJ, et al. Oral oestradiol/ trimegestone replacement reduces procarbox-ypeptidase U (TAFI): a randomized, placebo-controlled, 12-week study in early postmenopausal women. J Intern Med 2002 Mar; 251 (3): 245-251
40. van Baal WM, Emeis JJ, van der Mooren MJ, et al. Impaired procoagulant-anticoagulant balance during hormone replacement therapy? A randomised, placebo-controlled 12-week study. Thromb Haemost 2000 Jan; 83 (1): 29-34
41. Archer DF. The effect of the duration of progestin use on the occurrence of endometrial cancer in postmenopausal women. Menopause 2001 Jul-Aug; 8 (4): 245-251
42. Grady D, Gebretsadik T, Kerlikowske K, et al. Hormone replacement therapy and endometrial cancer risk: a meta-analysis. Obstet Gynecol 1995 Feb; 85 (2): 304-313
43. Toni F, Lentini GM, Baldi S, et al. Endometrial histopathology and compliance of the treatment with nome-gestrolo acetate versus micronized vaginal progesterone in the transdermal estrogen replacement therapy [abstract]. 2nd International Symposium on Women's Health and Menopause; 1996 Dec 4-7; Florence
44. Williams JK, Honore EK, Washburn SA, et al. Effects of hormone replacement therapy on reactivity of atherosclerotic coronary arteries in cynomolgus monkeys. J Am Coll Cardiol 1994 Dec; 24 (7): 1757-1761
45. Williams JK, Cline JM, Honore EK, et al. Coadministration of nomegestrol acetate does not diminish the beneficial effects of estradiol on coronary artery dilator responses in nonhuman primates (Macaca fascicularis). Am J Obstet Gynecol 1998 Nov; 179 (5): 1288-1294
46. Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy post-menopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002 Jul 17; 288 (3): 321-333
47. Chakhtoura Z, Canonico M, Gompel A, et al. Progestogenonly contraceptives and the risk of stroke: a meta-analysis. Stroke 2009; 40 (4): 1059-1062
48. Gerich JE. Type 2 diabetes mellitus is associated with multiple cardiometabolic risk factors. Clin Cornerstone 2007; 8 (3): 53-68
49. The Writing Group for the PEPI Trial. Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women: the Postmenopausal Estrogen/ Progestin Interventions (PEPI) Trial. JAMA 1995 Jan 18; 273 (3): 199-208
50. Dorangeon P, Thomas JL, Gillery P, et al. Short term effects on lipids and lipoproteins of two progesterones used in postmenopausal replacement therapy. Eur J Clin Res 1992; 3: 187-193
51. Dorangeon P, Thomas JL, Choisy H, et al. Effects of nomegestrol acetate on carbohydrate metabolism. Diabete Metab 1993 Sep-Oct; 19 (5): 441-445
52. Gol M, Akan P, Dogan E, et al. Effects of estrogen, raloxifene, and hormone replacement therapy on serum C-reactive protein and homocysteine levels. Maturitas 2006 Feb 20; 53 (3): 252-259
53. Beral V. Breast cancer and hormone-replacement therapy in the Million Women Study. Lancet 2003 Aug 9; 362 (9382): 419-427
54. Speroff L. The Million Women Study and breast cancer. Maturitas 2003 Sep 25; 46 (1): 1-6
55. Shields-Botella J, Chetrite G, Meschi S, et al. Effect of nomegestrol acetate on estrogen biosynthesis and transformation in MCF-7 and T47-D breast cancer cells. J Steroid Biochem Mol Biol 2005 Jan; 93 (1): 1-13
56. Chetrite G, Paris J, Botella J, et al. Effect of nomegestrol acetate on estrone-sulfatase and 17beta-hydroxysteroid dehydrogenase activities in human breast cancer cells. J Steroid Biochem Mol Biol 1996 Aug; 58 (5-6): 525-531
57. Chetrite GS, Thomas JL, Shields-Botella J, et al. Control of sulfatase activity by nomegestrol acetate in normal and cancerous human breast tissues. Anticancer Res 2005 Jul-Aug; 25 (4): 2827-2830
58. Chetrite GS, Paris J, Shields-Botella J, et al. Effect of nomegestrol acetate on human estrogen sulfotransferase activity in the hormone-dependent MCF-7 and T-47D breast cancer cell lines. Anticancer Res 2003 Nov-Dec; 23 (6C): 4651-4655
59. Botella J, Duranti E, Duc I, et al. Inhibition by nomegestrol acetate and other synthetic progestins on proliferation and progesterone receptor content of T47-D human breast cancer cells. J Steroid Biochem Mol Biol 1994 Jul; 50 (1-2): 41-47
60. Catherino WH, Jeng MH, Jordan VC. Norgestrel and gestodene stimulate breast cancer cell growth through an oestrogen receptor mediated mechanism. Br J Cancer 1993 May; 67 (5): 945-952
61. Catherino WH, Jordan VC. Nomegestrol acetate, a clinically useful 19-norprogesterone derivative which lacks estrogenic activity. J Steroid Biochem Mol Biol 1995 Nov; 55 (2): 239-246
62. Nguyen-Pascal ML, Thomas JL, Bergougnoux L, et al. Nomegestrol acetate may enhance the skeletal effects of estradiol on biochemical markers of bone turnover in menopausal women after a 12-week treatment period. Climacteric 2005 Jun; 8 (2): 136-145
63. Cohen A, Denis C, Thomas JL. Treatment of perimenopausal women with 5mg/d of nomegestrol acetate for 20 days of the cycle. Contracept Fertil Sex (Paris) 1992; 20 (11): 1054-1057
64. Medical News Today. Pivotal phase IIIa trials for Organon's novel oral contraceptive, NOMAC/E2: complete recruitment [online]. Available from URL: http://www.medical newstoday.com/articles/71276.php [Accessed 2010 Jan 14]
65. Schering-Plough. Efficacy and safety study of the combined oral contraceptive NOMAC-E2 compared to a COC containing DRSP/EE (292002) [COMPLETED] (P05722) [ClinicalTrials.gov identifier NCT00413062]. US National Institutes of Health, ClinicalTrials.gov [online]. Available from URL: http://www. clinicaltrials.gov [Accessed 2010 Feb 5]
66. Schering-Plough. Effects on ovarian function of the combined oral contraceptive NOMAC-E2 compared to a COC containing DRSP/EE (292003) [COMPLETED] (P05723) [ClinicalTrials.gov identifier NCT00511433]. US National Institutes of Health, ClinicalTrials.gov [online]. Available from URL: http://www. clinicaltrials.gov [Accessed 2010 Feb 5]